Market Research Logo

Global Viral Vector Vaccines Market Forecasts 2019-2027

Global Viral Vector Vaccines Market Forecasts 2019-2027

KEY FINDINGS

The global market for viral vector vaccines is expected to grow at a CAGR of 18.19% over the forecast period of 2019-2027. Promising results from several clinical studies performed by various organizations have emphasized the potential of viral-vector-based vaccines and therapies for gene therapies.

MARKET INSIGHTS

The global market for viral vector vaccines is segmented on the basis of types, applications and diseases. The global viral vector vaccine manufacturing market by type segment comprises adenoviral vectors, retroviral vectors, lentivirus vectors, adeno-associated viral vectors, cytomegalovirus, and other viral vectors. Key strategic initiatives being undertaken by companies to expand their viral vector manufacturing capabilities are also expected to drive notable growth across the global viral vector vaccine manufacturing market over the forecast period.

REGIONAL INSIGHTS

Geographically the global viral vector vaccine manufacturing market has been segmented into North America, Europe, Asia-Pacific and Rest of the World. Among these regions, the European market holds the largest share. The reason for this can possibly be a rise in the livestock diseases in the region, which is fueling the market for viral vector vaccine manufacturing as these viral-vectors-based vaccines are highly adapted for the prevention of livestock diseases. Heavy investment in related R&D is also expected to increase the vaccine production capacity.

COMPETITIVE INSIGHTS

Leading market players in the global viral vector vaccines manufacturing market are Advanced Biotherapeutics Consulting, Advanced Bioscience Laboratories Inc., Applied Viromics, Batavia Biosciences, Benitec Biopharma, Biogen Idec (Now Biogen Inc.), Biovian, Brammer Bio, Boehringer Ingelheim Gmbh, Cell and Gene Therapy Catapult, Ceva Corporate, Cobra Biologics (Subsidiary Of Recip Ab), Ge Healthcare, Janssen Pharmaceutical Inc. and ID Pharma Co. Ltd.


1. Research Scope
1.1. Study Goals
1.2. Scope Of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study And Forecasting Years
2. Research Methodology
2.1. Sources Of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top Down Approach
2.3. Bottom-up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
3.2. Key Findings
3.2.1. Pox Virus Constitutes The Largest Market Share In Terms Of Types
3.2.2. Human Diseases Are Anticipated To Grow Significantly During The Forecast Period
3.2.3. Multivalent Applications Are Widely Used In The Viral Vector Manufacturing Market
4. Market Determinants
4.1. Market Drivers
4.1.1. Promising Results From Several Clinical Studies
4.1.2. Mounting Number Of Viral Vectors Gene-therapy-based Clinical Trials
4.1.3. Growing Chronic Diseases
4.2. Market Opportunities
4.2.1. Swelling Investment In Gene-therapy-based R&D Activities
4.2.2. Increase In The Research And Development
4.3. Market Restraints
4.3.1. Poor Reimbursement System
4.3.2. Stringent Government Policies
4.4. Market Challenges
4.4.1. Unfavourable Compensation Situation
4.4.2. Pricing Pressure Coupled With Lack Of Product Differentiation
4.4.3. Rigorous Regulatory Agenda
5. Market Segmentation
5.1. Market By Types 2019-2027
5.1.1. Adenoviral Vectors
5.1.2. Retroviral Vectors
5.1.3. Lentiviral Vectors
5.1.4. Adeno-associated Viral Vectors
5.1.5. Poxvirus
5.1.6. Cytomegalovirus
5.1.7. Other Viral Vectors
5.2. Market By Application 2019-2027
5.2.1. Multivalent
5.2.2. Multipathogen
5.3. Market By Diseases 2019-2027
5.3.1. Human Diseases
5.3.1.1. Hepatitis
5.3.1.2. Cancer
5.3.1.3. Malaria
5.3.1.4. Tuberculosis
5.3.1.5. Influenza
5.3.1.6. Hiv
5.3.1.7. Other Human Diseases
5.3.2. Veterinary Diseases
5.3.2.1. Avian Influenza
5.3.2.2. Marek's Disease
5.3.2.3. Infectious Bronchitis
5.3.2.4. Ppr Disease
5.3.2.5. Other Veterinary Diseases
6. Key Analytics
6.1. Evolution And Transition
6.2. Regulatory Framework
6.2.1. The United States
6.2.2. European Union
6.2.3. Asia Pacific
6.2.3.1. Australia
6.2.3.2. Japan
6.2.3.3. India
6.2.3.4. China
6.3. Key Properties Of Viral Vector
6.4. Characteristics Of Potential Viral Vaccine Vectors
6.5. Patent Analysis
6.5.1. The United States Patent Analysis
6.5.2. Europe Patent Analysis
6.5.3. Japan Patent Analysis
6.6. Manufacturing Process Of A Viral-vector
6.7. Small-scale Manufacturing Process Of Adenovirus
6.8. Key Suppliers In Viral Vector Market
6.9. Key Buying Criteria
7. Geographical Analysis
7.1. North America
7.1.1. The United States
7.1.2. Canada
7.2. Europe
7.2.1. Germany
7.2.2. The United Kingdom
7.2.3. France
7.2.4. Spain
7.2.5. Italy
7.2.6. Rest Of The Europe
7.3. Asia-pacific
7.3.1. China
7.3.2. India
7.3.3. Japan
7.3.4. Australia
7.3.5. South Korea
7.3.6. Rest Of Asia-pacific
7.4. Rest Of The World
7.4.1. Latin America
7.4.2. Middle East And Africa
8. Company Profiles
8.1. Advanced Biotherapeutics Consulting
8.2. Advanced Bioscience Laboratories Inc.
8.3. Applied Viromics
8.4. Batavia Biosciences
8.5. Benitec Biopharma
8.6. Biogen Idec (Now Biogen Inc.)
8.7. Biovian
8.8. Brammer Bio
8.9. Boehringer Ingelheim Gmbh
8.10. Cell And Gene Therapy Catapult
8.11. Ceva Corporate
8.12. Cobra Biologics (Subsidiary Of Recip Ab)
8.13. Ge Healthcare
8.14. Janssen Pharmaceutical Inc.
8.15. Id Pharma Co. Ltd.
Table List
Table 1 Global Viral Vector Vaccine Manufacturing Market By Geography 2019-2027 ($ Thousand)
Table 2 Ongoing Clinical Trials Related To Viral Vectors
Table 3 Various Viral Vectors Properties And Their Application In Gene Therapy
Table 4 Global Viral Vector Vaccine Manufacturing Market By Types 2019-2027 ($ Thousands)
Table 5 Key Viral Vectors Characteristics
Table 6 Global Viral Vector Vaccine Manufacturing Market In Adenoviral Vectors By Geography 2019-2027 ($ Thousands)
Table 7 Global Viral Vector Vaccine Manufacturing Market In Retroviral Vectors By Geography 2019-2027 ($ Thousands)
Table 8 Advantages And Disadvantages Of Retroviral Vectors
Table 9 Components Of Hiv Provirus
Table 10 Global Viral Vector Vaccine Manufacturing Market In Lentiviral Vectors By Geography 2019-2027 ($ Thousands)
Table 11 Second- Vs. Third-generation Lentiviral Systems
Table 12 Aav Vectors With Their Tropisms And Receptors
Table 13 Global Viral Vector Vaccine Manufacturing Market In Adeno-associated Viral Vectors By Geography 2019-2027 ($ Thousands)
Table 14 Licensed Fowl Pox Viral-vectored Veterinary Vaccines
Table 15 Global Viral Vector Vaccine Manufacturing Market In Pox Virus By Geography 2019-2027 ($ Thousands)
Table 16 Global Viral Vector Vaccine Manufacturing Market In Cytomegalovirus By Geography 2019-2027 ($ Thousands)
Table 17 Global Viral Vector Vaccine Manufacturing Market In Other Viral Vectors By Geography 2019-2027 ($ Thousands)
Table 18 Global Viral Vector Vaccine Manufacturing Market By Application 2019-2027 ($ Thousands)
Table 19 Global Viral Vector Vaccine Manufacturing Market In Multivalent By Geography 2019-2027 ($ Thousands)
Table 20 Region Wise Tb Statistics For 2016
Table 21 Global Viral Vector Vaccine Manufacturing Market In Multipathogen By Geography 2019-2027 ($ Thousands)
Table 22 Global Viral Vector Vaccine Manufacturing Market By Diseases 2019-2027 ($ Thousands)
Table 23 Global Viral Vector Vaccine Manufacturing Market In Human Diseases By Geography 2019-2027 ($ Thousands)
Table 24 Global Viral Vector Vaccine Manufacturing Market In Human Diseases By Types 2019-2027 ($ Thousands)
Table 25 Global Human Diseases Market In Hepatitis By Geography 2019-2027 ($ Thousands)
Table 26 Estimated Actual New Cases Of Hav
Table 27 Global Human Diseases Market In Cancer By Geography 2019-2027 ($ Thousands)
Table 28 Estimated New Cancer Cases In The United States 2017
Table 29 Global Human Diseases Market In Malaria By Geography 2019-2027 ($ Thousands)
Table 30 Malaria Vaccine Development Initiatives
Table 31 Viral Vector Vaccine Candidates For Tuberculosis
Table 32 Global Human Diseases Market In Tuberculosis By Geography 2019-2027 ($ Thousands)
Table 33 Global Human Diseases Market In Influenza By Geography 2019-2027 ($ Thousands)
Table 34 Benefits And Concern For Virus-vectored Experimental Influenza Vaccines
Table 35 Global Human Diseases Market In Hiv By Geography 2019-2027 ($ Thousands)
Table 36 Global Human Diseases Market In Other Human Diseases By Geography 2019-2027 ($ Thousands)
Table 37 Ongoing Clinical Trials And Development In Zika Virus Vaccine
Table 38 Licensed Viral-vectored Veterinary Vaccines
Table 39 Global Viral Vector Vaccine Manufacturing Market In Veterinary Diseases By Geography 2019-2027 ($ Thousands)
Table 40 Global Viral Vector Vaccine Manufacturing Market In Veterinary Diseases By Types 2019-2027 ($ Thousands)
Table 41 Avian Influenza Vaccines
Table 42 Global Veterinary Diseases Market In Avian Influenza By Geography 2019-2027 ($ Thousands)
Table 43 Global Veterinary Diseases Market In Marek's Disease By Geography 2019-2027 ($ Thousands)
Table 44 Marek’s Disease Vaccines
Table 45 Global Veterinary Diseases Market In Infectious Bronchitis By Geography 2019-2027 ($ Thousands)
Table 46 Global Veterinary Diseases Market In Ppr Disease By Geography 2019-2027 ($ Thousands)
Table 47 Global Veterinary Diseases Market In Other Veterinary Diseases By Geography 2019-2027 ($ Thousands)
Table 48 Global Viral Vector Vaccine Manufacturing Market By Geography 2019-2027 ($ Thousands)
Table 49 North America Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Table 50 Funding In Cancer Research In The United States ($ Millions)
Table 51 The United States Viral Vector Vaccine Manufacturing Market By Types 2019-2027 ($ Thousands)
Table 52 Nih Funding For Crispr-related Research 2006-2016 ($)
Table 53 Canada Viral Vector Vaccine Manufacturing Market By Types 2019-2027 ($ Thousands)
Table 54 Europe Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Table 55 Germany Viral Vector Vaccine Manufacturing Market 2019-2027 By Types ($ Thousands)
Table 56 The United Kingdom Viral Vector Vaccine Manufacturing Market By Types 2019-2027 ($ Thousands)
Table 57 France Viral Vector Vaccine Manufacturing Market By Types 2019-2027 ($ Thousands)
Table 58 Spain Viral Vector Vaccine Manufacturing Market By Types 2019-2027 ($ Thousands)
Table 59 Italy Viral Vector Vaccine Manufacturing Market By Types 2019-2027 ($ Thousands)
Table 60 Asia-pacific Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Table 61 China Viral Vector Vaccine Manufacturing Market 2019-2027 By Types ($ Thousands)
Table 62 Ongoing Preclinical And Clinical Trials Of Hiv/Aids Vaccine In China
Table 63 Prevalence Of Tuberculosis In India 2016
Table 64 Indiaviral Vector Vaccine Manufacturing Market 2019-2027 By Types ($ Thousands)
Table 65 Clinical Trials Related To Hiv Vaccine In India
Table 66 Japan Viral Vector Vaccine Manufacturing Market 2019-2027 By Types ($ Thousands)
Table 67 Australia Viral Vector Vaccine Manufacturing Market 2019-2027 By Types ($ Thousands)
Table 68 South Korea Viral Vector Vaccine Manufacturing Market 2019-2027 By Types ($ Thousands)
Table 69 Principal Causes Of Deaths In Singapore, 2014–2016
Table 70 Number Of Hiv And Aids People In Thailand 2016
Table 71 Rest Of World Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Table 72 Latin America Viral Vector Vaccine Manufacturing Market 2019-2027 By Types ($ Thousands)
Table 73 Causes Of Death In Cuba And Percentage Change From 2005-2016
Table 74 Middle East And Africa Viral Vector Vaccine Manufacturing Market 2019-2027 By Types ($ Thousands)
Table 75 Characteristics Of The Priority Diseases Identified By The Who R&D Blueprint In Mea 2017
Figures List
Figure 1 Global Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousand)
Figure 2 Schematic Overview Of Multivalent And Multipathogen Viral Vector Vaccines
Figure 3 Region Wise Estimation Of People Living With Hiv 2016 (Million)
Figure 4 Region Wise Prevalence Of Hbv Infection In The General Population 2015 (Millions)
Figure 5 Confirmed, Probable And Suspected Evd Cases Worldwide
Figure 6 Poultry Production Estimates Worldwide (Million Metric Tons)
Figure 7 Vaccine Advancements Timeline
Figure 8 Steps Requirement For Vaccine Approval
Figure 9 Vaccine Review And Regulation Steps Under Fda
Figure 10 Vaccine Review And Regulation Steps Under Ema
Figure 11 Vaccine Review And Regulation Steps Under Mhlw
Figure 12 Approval Process Of Vaccine In India
Figure 13 Manufacturing Process Of Adenovirus
Figure 14 The United States Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Figure 15 Canada Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Figure 16 Germany Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Figure 17 The United Kingdom Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Figure 18 Number Of People Living With Hiv In France
Figure 19 France Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Figure 20 Leading Causes Of Women Death In France (%)
Figure 21 Leading Causes Of Men Death In France (%)
Figure 22 Spain Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Figure 23 Number Of People In Spain Infected With Hiv
Figure 24 Italy Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Figure 25 Rest Of The Europe Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Figure 26 Number Of People In Rest Of Europe Infected With Hiv (Thousands)
Figure 27 China Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Figure 28 India Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Figure 29 Japan Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Figure 30 Number Of Hiv Cases In Japan 2012 And 2016
Figure 31 Australia Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Figure 32 Various Viral Vaccine Vectors Used In Aids Vaccine Development
Figure 33 Number Of Diagnosed Hiv Infections In Australia 2012–2016
Figure 34 South Korea Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Figure 35 Shares Of Death In South Korea In 2016 Death Rate (Per 100,000 Populations)
Figure 36 Rest Of Asia-pacific Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Figure 37 Diagnosed Hiv Cases In The Philippines By Age Group 2016 (%)
Figure 38 Latin America Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Figure 39 Middle East And Africa Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report